导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.11% | 84/108 |
| 近一周 | -3.07% | 54/119 |
| 近一月 | -2.15% | 12/121 |
| 近一季 | -3.64% | 43/117 |
| 近半年 | -9.69% | 74/111 |
| 近一年 | -11.45% | 57/99 |
| 近两年 | 34.65% | 66/94 |
| 近三年 | 24.05% | 52/74 |
| 成立以来 | -7.85% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.04% 78/109 |
-10.50% 93/119 |
- - |
- - |
| 2025 | 31.59% 46/108 |
2.68% 61/97 |
8.79% 62/99 |
20.58% 39/104 |
-2.30% 43/108 |
| 2024 | 16.42% 38/97 |
1.48% 49/89 |
4.37% 39/94 |
13.18% 32/97 |
-2.88% 57/97 |
| 2023 | -16.69% 56/93 |
-3.01% 56/73 |
-8.60% 48/77 |
-0.46% 13/82 |
-5.58% 78/93 |
| 2022 | -15.00% 19/71 |
-15.81% 24/58 |
8.70% 20/62 |
-17.28% 45/68 |
12.29% 18/71 |
| 2021 | -25.93% 37/58 |
-3.97% 285/312 |
-0.45% 247/328 |
-15.05% 269/358 |
-8.80% 42/58 |
| 2020 | 28.51% 19/38 |
-8.40% 102/280 |
19.42% 101/295 |
5.66% 88/299 |
11.19% 108/305 |
| 2019 | 18.61% 21/30 |
12.71% 77/258 |
-2.09% 215/268 |
-1.66% 178/253 |
9.30% 82/266 |
| 2018 | -14.65% 14/28 |
- - |
- - |
- - |
-10.34% 112/241 |
| 2017 | 34.44% 6/20 |
- - |
- - |
- - |
- - |
| 2016 | 5.22% 9/17 |
- - |
- - |
- - |
- - |
| 2015 | -4.10% 9/16 |
- - |
- - |
- - |
- - |
| 2014 | - 62/99 |
- - |
- - |
- - |
- - |
| 2013 | 7.33% 33/70 |
- - |
- - |
- - |
- - |
| 2012 | 19.46% 5/51 |
- - |
- - |
- - |
- - |
| 2011 | -24.08% 24/27 |
- - |
- - |
- - |
- - |
| 2010 | -2.59% 8/9 |
- - |
- - |
- - |
- - |
| 2009 | 57.95% 5/9 |
- - |
- - |
- - |
- - |
| 2008 | -49.37% 2/3 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 摩根中国生物医药混合(QDII)A | 1.4779 | 17.64% |
| 摩根中国生物医药混合(QDII)C | 1.4554 | 17.49% |
| 南方港股医药行业混合发起(QDII)A | 1.3423 | 15.29% |
| 南方港股医药行业混合发起(QDII)C | 1.2936 | 15.12% |
| 东方红医疗创新混合(QDII)A | 0.8769 | 15.09% |
| 东方红医疗创新混合(QDII)C | 0.8725 | 14.94% |
| 万家全球成长一年持有期混合(QDII)A | 0.9681 | 12.64% |
| 万家全球成长一年持有期混合(QDII)C | 0.9395 | 12.46% |
| 长城港股医疗保健精选混合发起(QDII)A | 0.7593 | 8.70% |
| 富国医药精选混合(QDII)A | 0.9730 | 8.69% |
| 嘉实海外中国股票混合 VS. 建信新兴市场混合(QDII)A(539002) |